Researcher at Delta Biosciences running experiments. (Image: Delta Biosciences)
Delta Biosciences, a Lithuanian startup, is developing a next-generation screening platform to accelerate new drug discovery. CERN’s cutting-edge know-how in micro-engineering is particularly pertinent to the company’s advances in microscale detection systems. A novel way to manufacture highly-customisable microvias, useful in electronics applications, was invented by experts at CERN. This technology is helping the startup further miniaturise its screening capabilities, which is essential on the road to discovering novel therapies.